An Alzheimer’s blood test is getting popular. But who really needs it?

Richard Mayeux, MD, MSc, Chair of the Department of Neurology at Columbia University Irving Medical Center and Co-Director of the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, comments on the ongoing TRAILBLAZER-3 trial, a study in which he is not involved. “People keep thinking or talking about early treatment,” says Dr. Mayeux. “What you want to do is get to that fine area just before cognitive impairment starts to occur.” He also discusses findings from his research involving data from over 8,500 individuals in the U.S. and the Dominican Republic, focusing on identifying the risk of developing Alzheimer’s disease—a presentation he delivered at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) meeting last month in Copenhagen, Denmark. [read more]

Source: Science